Page 2 - Dominic Smethurst News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors

Anti-tumor activity observed in heavily pre-treated patients with EphA2-positive ovarian and urothelial cancers; overall response rates of 22% and 67%, respectively Emergent safety profile of. | September 7, 2022

United kingdomUnited statesDominic smethurstKevin leeBicycle therapeuticsChief medical officerBicycle toxin conjugateChief executive officerResponse evaluation criteriaSolid tumorsCancer research united kingdom centreBicycle therapeutics plc stock exchangePress releaseRofile bcyc us0887861088

Bicycle Therapeutics reports promising BT8009 study results, shares tank 30%

Bicycle Therapeutics reports promising Phase 1/2 BT8009 study results confirming preliminary anti-tumor results

United statesDominic smethurstKevin leeAmerican association for cancer research annual meetingBicycle therapeuticsMedical officer dominic smethurstAmerican associationCancer research annual meeting

Bicycle Therapeutics Reports Interim BT8009 Phase I Clinical Trial Results

Bicycle Therapeutics Reports Interim BT8009 Phase I Clinical Trial Results
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

United statesDominic smethurstKevin leeBicycle therapeuticsAmerican association for cancer research annual meetingBicycle therapeutics limitedSunday aprilChief medical officerChief executive

Bicycle Therapeutics plc: Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial

BT5528 Phase I anti-tumor activity observed in late line patients, with 2 partial responses out of 2 urothelial cancer patients dosed and an 80% disease control rate in 5 EphA2-positive ovarian cancer

United statesUnited kingdomMedimmune ephDavid borahDominic smethurstMary jane elliottKevin leeExchange commissionConsilium strategic communicationsBicycle toxin conjugatesChief medical officerChief executive officerResponse evaluation criteriaSolid tumorsInvestors mediaBicycle toxin conjugate